Close Menu

NEW YORK — New Horizon Health said today that it has signed an agreement to commercialize its ColoClear colorectal cancer test in Hong Kong and certain other Asian markets with Prenetics.

According to New Horizon Health, which is based in Hangzhou, China, ColoClear is a stool-based DNA test specifically designed to detect colon cancer in individuals of Asian descent, with 92 percent sensitivity demonstrated in clinical studies. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Master's and doctoral students in the UK call on funding groups to extend their grants for the duration of the disruption caused by the COVID-19 outbreak, the Guardian reports.

Squid can make edits to their RNA within the cytoplasm of their axons, Science News reports.

The Chan Zuckerberg Initiative is putting $25 million toward COVID-19 treatment research, according to the Verge.

In Science this week: researchers engineer version of Cas9 that is nearly PAM-less, and more.

Sponsored by

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.